NCT06450366: A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- State
- Completed
- Phase
- Phase 3
- People
- 301 taking part
- Started
- 8 Jul 2024
- Primary completion
- 14 Feb 2025
- Arms
- Enlicitide
- Results
- Posted on the registry
- 10 Jun 2024: Trial registered
- 8 Jul 2024: Trial started
- 28 Mar 2025: Trial completed
- 27 Mar 2026: Trial results posted